You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

ELIDEL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Elidel patents expire, and when can generic versions of Elidel launch?

Elidel is a drug marketed by Bausch and is included in one NDA.

The generic ingredient in ELIDEL is pimecrolimus. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the pimecrolimus profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Elidel

A generic version of ELIDEL was approved as pimecrolimus by ACTAVIS LABS UT INC on December 27th, 2018.

  Try a Trial

Summary for ELIDEL
Drug patent expirations by year for ELIDEL
Drug Prices for ELIDEL

See drug prices for ELIDEL

Recent Clinical Trials for ELIDEL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
St Joseph University, Beirut, LebanonPhase 2/Phase 3
PfizerPhase 4
Glenmark Pharmaceuticals Ltd. IndiaPhase 3

See all ELIDEL clinical trials

Pharmacology for ELIDEL

US Patents and Regulatory Information for ELIDEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch ELIDEL pimecrolimus CREAM;TOPICAL 021302-001 Dec 13, 2001 AB RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ELIDEL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bausch ELIDEL pimecrolimus CREAM;TOPICAL 021302-001 Dec 13, 2001 ⤷  Try a Trial ⤷  Try a Trial
Bausch ELIDEL pimecrolimus CREAM;TOPICAL 021302-001 Dec 13, 2001 ⤷  Try a Trial ⤷  Try a Trial
Bausch ELIDEL pimecrolimus CREAM;TOPICAL 021302-001 Dec 13, 2001 ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ELIDEL

See the table below for patents covering ELIDEL around the world.

Country Patent Number Title Estimated Expiration
Greece 3017858 ⤷  Try a Trial
Australia 714254 ⤷  Try a Trial
Israel 96268 Substituted cycloalkyl tricyclic macrolides containing heteroatoms their preparation and pharmaceutical compositions containing them ⤷  Try a Trial
Norway 971951 ⤷  Try a Trial
Japan 2006151999 CRYSTALLINE MACROLIDE AND PROCESS FOR PREPARATION THEREOF ⤷  Try a Trial
Austria 287410 ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ELIDEL

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0427680 91021 Luxembourg ⤷  Try a Trial
0427680 SZ 12/2003 Austria ⤷  Try a Trial PRODUCT NAME: PIMECROLIMUS, GEGEBENENFALLS IN FORM PHARMAZEUTISCH ANNEHMBARER SALZE
0427680 SPC/GB03/015 United Kingdom ⤷  Try a Trial PRODUCT NAME: PIMECROLIMUS OR SALTS OR ESTERS THEREOF; REGISTERED: DK 21034 (MT-NO.32700) 20020315; UK PL 00101/0659 20021003
0427680 12/2003 Austria ⤷  Try a Trial PRODUCT NAME: PIMECROLIMUS, GEGEBENENFALLS IN FORM PHARMAZEUTISCH ANNEHMBARER SALZE; NAT. REGISTRATION NO/DATE: 1-24689 20020917; FIRST REGISTRATION: DK 21034 20020315
0427680 300134 Netherlands ⤷  Try a Trial 300134, 20101107, EXPIRES: 20151106
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.